The best investment on the planet, both from a security and growth perspective, are the Canadian banks. And of the banks, TD is the best. I recently moved to 100% of my portfolio here and I look forward to all those Great White Shorts going bankrupt when the chickens come home to roost.
The last time TD did something like this it blew up. awe-som*sto-cks recently alerted this company i think. google them.
Here is the T again who post the sell to many Canadian bank boards.
Canadian banks are about to get hammered. Rising mortgage, home equity, and car loan delinquencies. Consumers are getting squeezed. Time to sell at the height of the credit bubble.
Perhaps a short-term pull back is more likely before the next rally on TD? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from https://hotstocks123.blogspot.com.
In the short-term TD does not seem to be like a good trade. Im not sure about you guys but awe-som_sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
I think TD is due for a pullback. What are your thoughts? if you guys have questions you should ask awe.some_sto-cks. They often respond to my emails which is helpful.
Is TD overvalued at current levels? Ive been struggling with this stock lately. Some of my other trades have been from awesome_sto-cks which are working out pretty well.
Toronto_Dominion Bank NYSE $TD Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0 In other words, the correlation coefficient of the other stocks is
Earnings big. Major stock buy-back. Capital surplus. Hope some short seller doesn't get a story planted about some schmuck who is ticked up about "excessive bad check fees". This stock should be way up today, but there will be efforts on the part of the shorts to depress the price before they cover their positions.
Why doesn't the Canadian side ride with the American it's the same company right? So if the American side goes up 80cents the Canadian should be up 1$ cdn.
TD has just seen the last of the selling. Looks like a potential push higher is in store. Im not sure about you guys but Awe-Some.Sto-ck.s has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Investors did not wait for Thus TD earning report to dump the stock as they did to its peers. Hope TD will not suffer the double down.
Charles A. Henriques NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration San Francisco Bay Area. 8,772 LinkedIn connections. Phd Scientists, Pharma Pros & Others.
Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. $1.9 Billion, sales worldwide.
The scenarios are quite interesting at current levels for TD. Im not sure about you guys but awe-some*sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Canadian banks performed much better than US banks. Analysts recommended US banks in past few months. They were wrong. TD is a strong and solid bank. With such a low PE and presence in US, the bank can benefit from both country economic growths in future.
Why is this stock performing so bad😩
Downside risk pretty much eliminated now I would guess, thoughts? Yo you should really check out awe.SOME-Stock-S, they seem on point with their stocks.